Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2024 16:05 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
January 05, 2024 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
January 04, 2024 22:46 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
January 03, 2024 16:25 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
January 03, 2024 06:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...
January 02, 2024 16:05 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
November 07, 2023 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at November Investor Conferences

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
October 30, 2023 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome...
September 28, 2023 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at October Investor Conferences

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
September 20, 2023 16:05 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne...